BioCardia (NASDAQ:BCDA – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock.
BioCardia Stock Performance
BCDA stock opened at $1.85 on Thursday. The firm has a market cap of $3.93 million, a P/E ratio of -0.44 and a beta of 1.28. BioCardia has a 1 year low of $1.84 and a 1 year high of $14.40. The stock has a 50-day simple moving average of $2.58 and a 200-day simple moving average of $3.33.
BioCardia (NASDAQ:BCDA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.78). On average, equities research analysts predict that BioCardia will post -5.06 EPS for the current year.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Featured Stories
- Five stocks we like better than BioCardia
- Do ETFs Pay Dividends? What You Need to Know
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- The How And Why of Investing in Oil Stocks
- Top-Performing Non-Leveraged ETFs This Year
- Using the MarketBeat Dividend Yield Calculator
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
